Research Article
Long-Term Outcome of Eyes with Vitrectomy for Submacular and/or Vitreous Hemorrhage in Neovascular Age-Related Macular Degeneration
Table 3
Anti-VEGF therapy before and after PPV.
| | | SMH | VH |
| | Number of eyes | 8 | 17 | | Before initial PPV | | No. eyes with anti-VEGF therapy | 2 (25.0%) | 8 (47.1%) | | No. of injections | 6.0 ± 4.2 (3–9) | 5.5 ± 5.4 (1–16) | | Time from initial anti-VEGF to PPV, months | 32.5 ± 10.6 (25–40) | 21.6 ± 15.3 (4–49) | | Duration of anti-VEGF therapy, months | 8.1 ± 7.5 (2.8–13.3) | 4.0 ± 2.9 (1.2–8.0) | | After initial PPV | | No. of eyes with anti-VEGF therapy | 6 (75.0%) | 7 (41.2%) | | No. of injections | 8.5 ± 4.9 (1–15) | 5.0 ± 3.1 (1–8) | | Time from PPV to final visit, months | 32.6 ± 6.7 (24–45) | 53.7 ± 21.4 (25–96) | | Duration of anti-VEGF therapy, months | 10.3 ± 17.1 (2.3–45.0) | 14.7 ± 10.7 (3.1–32.0) | | Time from PPV to anti-VEGF initiation, months | 6.5 ± 9.3 (1–25) | 8.4 ± 11.1 (1–32) | | Dry macula after PPV | 4 (50.0%) | 12 (70.6%) |
|
|
Data are expressed in number of patients (percentage) or mean ± standard deviation (range). unknown in two eyes. |
